Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Closed to Activation

Canadian Cancer Trials Group GA.2 (AG0212OG) -- (INTEGRATE): A Randomized Phase II Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Esophago-Gastric Cancer -- was closed to accrual on February 25, 2014 after successfully reaching its target accrual of 150 patients. Canadian centres randomized 17 patients and 3 remain on protocol treatment at this time.

Thank you to all participating centres, staff and patients for helping to make this trial a success.